https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42669 Wed 31 Aug 2022 16:25:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52432 Wed 11 Oct 2023 14:47:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54918 Thu 21 Mar 2024 13:12:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20861 Sat 24 Mar 2018 08:02:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17729 Sat 24 Mar 2018 07:57:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28075 2peak, 60 min, 4 d/week); ii) high intensity, low volume aerobic exercise (HI:LO, 70% VO_2peak, 45 min, 3 d/week); iii) low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO_2peak 45 min, 3 d/week); or iv) placebo (PLA). Liver fat (spectroscopy) and VAT (magnetic resonance imaging) were measured before and after intervention. Results: Forty-seven of the 48 (n = 12 in each group) participants completed the trial. There were no serious adverse events. There was a significant change in group x time interaction in liver fat, which reduced in HI:LO by 2.38 ± 0.73%, in LO:HI by 2.62 ± 1.00%, and in LO:LO by 0.84 ± 0.47% but not in PLA (increase of 1.10 ± 0.62%) (p = 0.04). There was a significant reduction in VAT in HI:LO (-258.38 ± 87.78 cm³), in LO:HI (-386.80 ± 119.5 cm³), and in LO:LO (-212.96 ± 105.54 cm³), but not in PLA (92.64 ± 83.46 cm³) (p = 0.03). There were no significant differences between the dose or intensity of the exercise regimen and reductions in liver fat or VAT (p >0.05). Conclusion: The study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss.]]> Sat 24 Mar 2018 07:39:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26621 Sat 24 Mar 2018 07:34:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35703 94 cm) were randomly allocated to consume fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10) or placebo (olive oil capsules) daily for 12 weeks. Liver fat was assessed using proton magnetic resonance spectroscopy. All outcomes were assessed at baseline and following 6 and 12 weeks of supplementation. Baseline liver fat was 4.6 ± 0.5% (range: 0.6 to 18.2%); 16 (32%) participants met the criteria for NAFLD (>5.5% liver fat). Repeated measures ANOVA revealed no significant time or group × time effect for fish oil versus placebo for liver fat, liver enzymes, anthropometry, or body composition including VAT (p > 0.05 for all), with similar finding for sub-analysis of participants with NAFLD. Omega-3 PUFA did not appear to be an effective agent for reducing liver fat in overweight men. The factors determining the health benefits of omega-3 PUFA supplementation on an individual level need to be clarified.]]> Fri 03 Dec 2021 10:33:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30121 Fri 03 Dec 2021 10:32:25 AEDT ]]>